Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
|
Results for 'Commercial Insight: Depression' |
|
|
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Psychopharmacotherapy Market Insights Obstacles & Opportunities in Mood Disorders & Cognitive Impairment, 2005-2012 |
Nov 2005 | £795 | 100% |
| Antiageing and Life Enhancement Pharmacotherapeutics | Jan 2006 | £795 | 89% |
| Stakeholder Opinions: Parkinson\'s Disease Review of Key Commercial Opportunities in the Symptomatic Treatment Market |
Jul 2006 | £1,335 | 88% |
| Personalized Medicine 2010 Assessing the Opportunities and Challenges in Commercializing Companion |
May 2010 | £1,580 | 85% |
| Advances in Neurostimulators | Apr 2010 | £4,110 | 83% |
| Commercial Insight: Antipsychotics Revenues of depots and new agents will partially offset generic erosion |
Oct 2009 | £9,615 | 75% |
| The Antipsychotics Market Insight & Analysis 2008 | Feb 2008 | £1,499 | 74% |
| Biobanking: Technologies and Global Markets | Jun 2011 | £3,065 | 65% |
| Commercial and Pipeline Perspectives: Obesity Lack of Reimbursement Limits Market Potential |
Dec 2006 | £7,210 | 64% |
| Neuromodulation Devices: World Market Prospects 2011-2021 |
Oct 2011 | £1,699 | 60% |
| Stakeholder Insight: Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines |
Dec 2006 | £8,365 | 59% |
| New Drug Futures 2009 | Jan 2012 | £1,995 | 55% |
| Weight Control Products | Feb 2011 | £2,845 | 48% |
- Results 1 - 13 of 13
-
-
- 1
-
-
